Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Lifted by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 421.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,382 shares of the biotechnology company's stock after purchasing an additional 38,292 shares during the period. Y Intercept Hong Kong Ltd's holdings in Sarepta Therapeutics were worth $3,024,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $31,000. UMB Bank n.a. boosted its position in shares of Sarepta Therapeutics by 53.0% in the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after buying an additional 276 shares during the period. Logan Capital Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $61,000. Finally, Hurley Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $76,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $0.95 during trading on Friday, reaching $11.93. 14,536,964 shares of the company's stock traded hands, compared to its average volume of 13,249,470. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $150.48. The company has a 50 day moving average of $26.12 and a 200-day moving average of $64.06. The stock has a market capitalization of $1.17 billion, a P/E ratio of -4.43 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. Sarepta Therapeutics's quarterly revenue was up 80.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.73 EPS. On average, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SRPT. UBS Group reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Evercore ISI downgraded shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price target on the stock. in a research note on Thursday, May 8th. Mizuho reaffirmed a "neutral" rating and set a $14.00 price target (down previously from $40.00) on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Wells Fargo & Company dropped their price target on shares of Sarepta Therapeutics from $65.00 to $48.00 and set an "overweight" rating on the stock in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Five equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $51.42.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.